Hoth Therapeutics (NASDAQ:HOTH) Receives Buy Rating from HC Wainwright

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 365.12% from the company’s previous close.

Several other equities analysts have also commented on HOTH. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Stock Performance

NASDAQ HOTH opened at $0.86 on Monday. The stock’s fifty day moving average is $0.89 and its two-hundred day moving average is $0.94. The firm has a market capitalization of $5.93 million, a P/E ratio of -0.53 and a beta of 0.84. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.15. As a group, sell-side analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.